Literature DB >> 9952

Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man.

W L Burland, W A Duncan, T Hesselbo, J G Mills, P C Sharpe, S J Haggie, J H Wyllie.   

Abstract

Cimetidine, a new H2-receptor antagonist, was safely administered to eighteen healthy man by the intravenous, intraduodenal or oral route. 2 When gastric secretion was maximally stimulated by either histamine or pentagastrin, the simultaneous administration of cimetidine produced marked inhibition of both acid and pepsin secretion. 3 Cimetidine was well absorbed by mouth and had a blood half-life of 2 hours. 4 Cimetidine was rapidly excreted via the kidneys and about 70% of the excreted material was unchanged drug. 5 Clinical evaluation of cimetidine in patients with peptic ulceration is recommended.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 9952      PMCID： PMC1402643          DOI： 10.1111/j.1365-2125.1975.tb00564.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  10 in total

1.  Inhibition of nocturnal acid secretion in duodenal ulcer by one oral dose of metiamide.

Authors:  G J Milton-Thompson; J G Williams; D J Jenkins; J J Misiewicz
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

2.  [The automatic determination of proteolytic activity of gastric juice].

Authors:  A M Cheret; S Bonfils
Journal:  Biol Gastroenterol (Paris)       Date:  1968

3.  Letter: Neutropenia associated with metiamide.

Authors:  J A Forrest; D J Shearman; R Spence; L R Celestin
Journal:  Lancet       Date:  1975-02-15       Impact factor: 79.321

4.  Letter: Metiamide in Zollinger-Ellison syndrome.

Authors:  M H Thompson; C W Vanables; I T Miller; J D Reed; D J Sanders; E R Grund; E L Blair
Journal:  Lancet       Date:  1975-01-04       Impact factor: 79.321

5.  Inhibition of gastric secretion in man by metiamide: a new, orally active histamine H 2 -receptor antagonist.

Authors:  J H Wyllie; W D Ealding; T Hesselbo; J W Plack
Journal:  Gut       Date:  1973-05       Impact factor: 23.059

6.  Metiamide--an orally active histamine H2-receptor antagonist.

Authors:  J W Black; W A Duncan; J C Emmett; C R Ganellin; T Hesselbo; M E Parsons; J H Wyllie
Journal:  Agents Actions       Date:  1973-10

7.  Metiamide, an H2-receptor blocker, as inhibitor of basal and meal-stimulated gastric acid secretion in patients with duodenal ulcer.

Authors:  M Mainardi; V Maxwell; R A Sturdevant; J I Isenberg
Journal:  N Engl J Med       Date:  1974-08-22       Impact factor: 91.245

8.  Relief of duodenal ulcer sysmptons by oral metiamide.

Authors:  R E Pounder; J G Williams; G J Milton-Thompson; J J Misiewicz
Journal:  Br Med J       Date:  1975-05-10

9.  Effect of histamine H2-receptor blockade on vagally induced gastric secretion in man.

Authors:  D C Carter; J A Forrest; M Werner; R C Heading; J Park; D J Shearman
Journal:  Br Med J       Date:  1974-08-31

10.  Gastric response to metiamide.

Authors:  B Thjodleifsson; K G Wormsley
Journal:  Br Med J       Date:  1974-05-11
  10 in total
  75 in total

1.  Editorial: Histamine antagonists and peptic ulcer.

Authors: 
Journal:  Br Med J       Date:  1976-04-03

2.  Cimetidine and ulcers.

Authors: 
Journal:  Br Med J       Date:  1976-11-27

3.  Cimetidine and ulcers.

Authors:  J J Misiewicz; W L Burland
Journal:  Br Med J       Date:  1976-12-11

4.  Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man.

Authors:  C W Howden; J A Forrest; J L Reid
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

5.  24-hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer during oral administration of cimetidine and atropine.

Authors:  R E Pounder; R H Hunt; S H Vincent; G J Milton-Thompson; J J Misiewicz
Journal:  Gut       Date:  1977-02       Impact factor: 23.059

6.  Effects of eight weeks' continuous treatment with oral ranitidine and cimetidine on gastric acid secretion, pepsin secretion, and fasting serum gastrin.

Authors:  R Mohammed; R J Holden; J B Hearns; B M McKibben; K D Buchanan; G P Crean
Journal:  Gut       Date:  1983-01       Impact factor: 23.059

7.  Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships.

Authors:  M Mignon; N P Chau; B K Nguyen-Phuoc; M Sauvage; F Leguy; S Bonfils
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 8.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

9.  Cimetidine-a clinical and pharmacokinetic study.

Authors:  J Webster; H E Barber; G M Hawksworth; T A Jeffers; J Petersen; J C Petrie; P W Brunt; N A Mowat; R Griffiths
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

10.  Cimetidine therapy does not prevent rebleeding from peptic ulceration.

Authors:  D L Carr-Locke; D Taverner; A C Wicks
Journal:  Postgrad Med J       Date:  1984-06       Impact factor: 2.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.